# Clinical Cancer Research

## Table of Contents

### Highlights of This Issue 1973

#### SPECIAL FEATURES

**CCR 20th Anniversary Commentary**

1975  
**CCR 20th Anniversary Commentary: Setting the Stage for Nanoparticle Albumin-Bound Paclitaxel—How Far Science Has Come**  
Sami I. Bashour and Nuhad K. Ibrahim

**CCR Translations**

1978  
**PLEKH5: A Key to Unlock the Blood–Brain Barrier?**  
Sylvia C. Eisele, Corey M. Gill, Ganesh M. Shankar, and Priscilla K. Brastianos  
*See related article, p. 2138*

1981  
**The Yin and Yang of Alloreactivity: Chronic Graft-versus-Host Disease and Leukemia Relapse**  
Saar Gill  
*See related article, p. 2020*

#### CCR New Strategies

1984  
**New Strategies in Glioblastoma: Exploiting the New Biology**  
Howard A. Fine

#### Molecular Pathways

1989  
**Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer**  
Lynnette Fernandez-Cuesta and Roman K. Thomas

1995  
**Molecular Pathways: A Novel Approach to Targeting Hypoxia and Improving Radiotherapy**  
*See related commentary, p. 1981*

#### Reviews

2001  
**Is This the Time to Introduce Minimal Residual Disease in Multiple Myeloma Clinical Practice?**  
Bruno Paiva, Noemi Puig, Ramón García-Sanz, and Jesús F. San Miguel on behalf of the Grupo Español de Mieloma (GEM)/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (PETHEMA) cooperative study groups

#### 2009 Genomic Landscape of Human Papillomavirus–Associated Cancers

Maria Rusan, Yvonne Y. Li, and Peter S. Hammerman

### CANCER THERAPY: CLINICAL

**2020 Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia**


*See related commentary, p. 1981*

### PERSONALIZED MEDICINE AND IMAGING

**2029 Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial**

Lorraine A. Chantrill, Adnan M. Nagrial, Clare Watson, Amber L. Johns, Mona Martynt-Smith, Skye Simpson, Scott Mead, Marc D. Jones, Jaswinder S. Samra, Anthony J. Gill, Nicole Watson, Venessa T. Chin, Jeremy L. Humphris, Angela Chou, Belinda Brown, Adrienne Money, Marina Pajic, Sean M. Grimmmond, David K. Chang, David Thomas, Lucille Sebastian, Katrin Sjoquist, Sonia Yip, Nick Pavlakis, Ray Asghari, Sandra Harvey, Peter Grimison, John Simes, and Andrew V. Blankin, on behalf of the Australian Pancreatic Cancer Genome Initiative (APGI) and the Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial Management Committee of the Australasian Gastrointestinal Trials Group (AGITG)

**2038 Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy**

Ursula Amstutz, Steven M. Offer, Johanna Sistonen, Markus Joerger, Robert B. Diasio, and Carlo R. Largia

**2045 Integrated Genomic Profiling, Therapy Response, and Survival in Adult Acute Myelogenous Leukemia**

Brian Parkin, Peter Ouilllette, Mehmet Yildiz, Kamlai Saiya-Cork, Kerby Shedden, and Sami N. Malek
Table of Contents

2057 MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial

2065 PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

2075 CD47 Enhances In Vivo Functionality of Artificial Antigen-Presenting Cells

2084 Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency

2096 Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma

2107 Chemotherapy Rescues Hypoxic Tumor Cells and Induces Their Reoxygenation and Repopulation—An Effect That Is Inhibited by the Hypoxia-Activated Prodrug TH-302

2115 Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors

2127 Rac1/Paki1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer

CANCER THERAPY: PRECLINICAL

BIOLOGY OF HUMAN TUMORS

2138 PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis

2148 The Impact of Clone Size on the Prognostic Value of Chromosome Aberrations by Fluorescence In Situ Hybridization in Multiple Myeloma

2157 Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
Table of Contents

2167  IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma

2177  Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte–Derived HLA-Ligandome Using a Reverse Immunology Approach
Pleun Hombrink, Chopie Hassan, Michel G.D. Kester, Lorenz Jahn, Margot J. Pont, Arnoud H. de Ru, Comelis A.M. van Bergen, Marieke Griffioen, J.H. Frederik Falkenburg, Peter A. van Veelen, and Mirjam H.M. Heemskerk

2187  RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer—Letter
Steven Sorscher

2188  RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer—Response
Rona Yaeger and Leonard B. Saltz

RETRACTION
2189  Retraction: Glioma-Associated Cancer-Initiating Cells Induce Immunosuppression

CORRECTIONS
2190  Correction: Associations and Interactions between Ets-1 and Ets-2 and Coregulatory Proteins, SRC-1, AIB1, and NCoR in Breast Cancer
2192  Correction: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

LETTERS TO THE EDITOR

2187  RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer—Letter
Steven Sorscher

ABOUT THE COVER
The cover shows establishment of blood brain barrier (BBB) tight junctions. Immunofluorescence staining demonstrates ZO-1 expression within the top endothelial layer of an in vitro BBB. For details, see the article by Jilaveanu and colleagues on page 2138 of this issue.